Clinical Trials on Cholangiocarcinoma; With Hepatocellular Carcinoma in South Africa

Total 130 results

National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Metastatic Cholangiocarcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Stage III Liver Cancer | Stage IV Liver Cancer

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Medical University of South Carolina

Active, not recruiting

90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Completed

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Cholangiocarcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Institut de Recherches Internationales Servier

Completed

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

Metastatic Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States, Spain, Korea, Republic of, Italy, France, United Kingdom
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditions

United States, Canada, Puerto Rico
South West Sydney Local Health District

Unknown

Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (DOSE-HEP)

Hepatocellular Cancer

Australia
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
TaiRx, Inc.

Terminated

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Cancer

Taiwan, United States
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany, Australia, Hong Kong, Switzerland, Spain, France, United States
Concord Repatriation General Hospital

Recruiting

HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

HCC | Hepatocellular Carcinoma

Australia, New Zealand
National Cancer Centre, Singapore
Iqvia Pty Ltd; Singapore Clinical Research Institute; Asia-Pacific Hepatocellular...

Completed

Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry (INSIGHT)

Hepatocellular Carcinoma

China, Korea, Republic of, Taiwan, Australia, Hong Kong, Singapore, New Zealand, Japan, Thailand
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Tularik

Terminated

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

United States, Russian Federation, United Kingdom, Singapore, Thailand, Ukraine, Brazil, China, Poland, Puerto Rico, South Africa
Erasmus Medical Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Recruiting

Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy (FIBROPANC-1)

Pancreatic Fistula | Pancreas Neoplasm | GIST | Neuroendocrine Carcinoma of Pancreas | Duodenum Carcinoma | Distal Cholangiocarcinoma | Pancreas Fibrosis

Netherlands
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Advanced Hepatocellular Carcinoma

United States, China, Italy, Japan, Korea, Republic of, Poland, Spain, Switzerland, Taiwan
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Medical University of South Carolina
National Cancer Institute (NCI); Apogee Biotechnology Corporation

Withdrawn

A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States
Gabi Chiorean, MD
Sanofi; OSI Pharmaceuticals

Terminated

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Hepatocellular Carcinoma

United States
Medical University of South Carolina

Completed

Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial). (ACCESS)

Hepatic Carcinoma | Chemoembolizaton | Transarterial Embolization

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Progen Pharmaceuticals

Terminated

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma (PATHWAY)

Cancer | Hepatocellular Carcinoma | Primary Liver Cancer | Liver Cancer | Hepatoma

Hong Kong, Singapore, United States, Australia, Canada, Italy, Malaysia, Spain, Taiwan, Thailand
National Cancer Institute (NCI)

Completed

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma

United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, United Kingdom, Canada
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, France, Korea, Republic of, China, Japan, Spain, Belgium, Croatia, Brazil, Austria, Italy, Costa Rica, Germany, Israel, Thailand, Turkey, Russian Federation, United Kingdom, Taiwan, Philippines, India, Chile, Finland, Greece, Sl... and more
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Hilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditions

United States
Merit Medical Systems, Inc.

Terminated

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer (HiQuality)

Hepatocellular Carcinoma

United States, France, Belgium, Greece, Italy
Eisai Limited
Merck Sharp & Dohme LLC

Completed

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Italy, Korea, Republic of, Poland, United States, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Japan, Malaysia, Philippines, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Royal North Shore Hospital

Active, not recruiting

Liver Function Investigation With SPECT (LiverINSPECT)

Liver Cancer, Adult

Australia
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
Apollomics (Australia) Pty. Ltd.
Novotech (Australia) Pty Limited; Apollomics Inc. (formerly CBT Pharmaceuticals...

Terminated

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Renal Cell Carcinoma | Hepatocellular Carcinoma

Australia, New Zealand
Exelixis

Completed

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Hepatocellular Carcinoma

Belgium, Hong Kong, Korea, Republic of, Canada, France, Taiwan, United States, Germany, Spain, United Kingdom, Singapore, Australia, Italy, Netherlands, Poland, Turkey, Ireland, New Zealand, Romania
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Completed

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy (METIV-HCC)

Hepatocellular Carcinoma

United States, France, Italy, Germany, Spain, Switzerland, Belgium, Portugal, Netherlands, Australia, Brazil, Canada, Austria, New Zealand, Sweden, Argentina
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Hepatocellular Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)

Hepatocellular Carcinoma

Germany, Romania, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Hong Kong, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland and more
Novartis Pharmaceuticals

Completed

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. (EVOLVE-1)

Carcinoma

China, Italy, Taiwan, Germany, Hungary, Belgium, Spain, Australia, Austria, France, Hong Kong, Thailand, Korea, Republic of, Canada, Japan, Israel, United States, Greece
Incyte Corporation

Recruiting

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Melanoma | Hepatocellular Carcinoma (HCC) | Renal Cell Carcinoma (RCC) | Colorectal Carcinoma (CRC) | Microsatellite Instability - High (MSI-H) | Mismatch Repair Deficient (dMMR)

United States, Canada, South Africa, Mexico
AstraZeneca

Active, not recruiting

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)

Hepatocellular Carcinoma

United States, Canada, France, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, India, Japan, Mexico, Russian Federation, China, Hong Kong, Australia, Spain, Singapore
Exact Sciences Corporation

Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Hepatitis B | Hepatocellular Carcinoma | Cirrhosis | Liver Cancer | Hepatocellular Cancer

United States
Incyte Corporation

Completed

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Cholangiocarcinoma

United States, France, Italy, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Korea, Republic of, Japan, Thailand
Target PharmaSolutions, Inc.

Recruiting

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Hepatocellular Cancer

United States, Germany, France, Italy, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Hepatocellular Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, New Zealand, Norway, Poland, Russian Federation, Spai... and more
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong

Clinical Trials on Cholangiocarcinoma; With Hepatocellular Carcinoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations